Cargando…
GM-CSF co-expressing DNA/MVA vaccine, prevention of acquisition by two series of SIVE660 challenges followed by a series of SIV251 challenges
Autores principales: | Robinson, H, Kannanganat, S, Gangadhara, S, Lai, L, Yu, T, Kozlowski, P, Earl, P, Moss, B, Amara, RR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441798/ http://dx.doi.org/10.1186/1742-4690-9-S2-P25 |
Ejemplares similares
-
OA07-03. Influence of preexisting vaccinia immunity on a DNA/MVA SIV vaccine, decreased cellular immunity but enhanced control of a pathogenic SIV challenge
por: Kannanganat, S, et al.
Publicado: (2009) -
CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012) -
Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012) -
SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251
por: Villefroy, Pascale, et al.
Publicado: (2006) -
ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIV(mac)251 Challenge
por: Alpert, Michael D., et al.
Publicado: (2012)